{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0050024\nAge: 62\nGender: Male\nSample ID: P-0050024-T02-IM6\nGene Panel: IMPACT468\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 30.0%\n=============\nDNA Variants:\nMET c.2937_3028+10del (p.X979_splice) - in 29.00% of 941 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nMET - nan (nan)\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Non-small cell lung cancer\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Capmatinib\",\n    \"Prior Treatment or Resistance Status\": \"N/A\",\n    \"Genomic Features\": \"MET exon 14 splice site mutation (c.2937_3028+10del, leading to MET exon 14 skipping)\",\n    \"FDA-approval status\": \"FDA-approved for metastatic NSCLC with MET exon 14 skipping alterations\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf\"\n  }\n}"
}